Literature DB >> 19200170

Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy.

U S Kristoffersen1, K Kofoed, G Kronborg, A K Giger, A Kjaer, A M Lebech.   

Abstract

OBJECTIVES: Antiretroviral therapy (ART) in HIV-infected patients is associated with increased cardiovascular risk. Circulating markers of endothelial dysfunction may be used to study early atherogenesis. The aim of our study was to investigate changes in such markers during initiation of ART.
METHODS: In 115 HIV-positive treatment-naïve patients, plasma lipids, E-selectin, soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule 1 (sVCAM-1), tissue-type plasminogen activator inhibitor 1 (tPAI-1) and high-sensitivity C-reactive protein (hsCRP) were measured before and after 2 and 14 months of ART. A control group of 30 healthy subjects was included. Values are mean+/-standard error of the mean.
RESULTS: Prior to treatment, HIV-infected patients had elevated levels of sICAM-1 (296+/-24 vs. 144+/-12 ng/mL), tPAI-1 (18 473+/-1399 vs. 5490+/-576 pg/mL) and hsCRP (28 060+/-5530 vs. 6665+/-2063 ng/mL) compared with controls (P<0.001). In contrast, sVCAM-1 and E-selectin did not differ between the groups. Initiation of ART resulted in significantly lower levels of E-selectin (15.1+/-0.8; P<0.01), sICAM-1 (248+/-12 ng/mL; P<0.05), sVCAM-1 (766+/-33 ng/mL; P<0.001) and hsCRP (14 708+/-2358 ng/mL; P<0.001) after 2 months, which remained reduced at 14 months. tPAI-1 was not influenced by initiation of ART.
CONCLUSIONS: Markers of endothelial dysfunction were elevated in treatment-naïve HIV-infected patients and were related to HIV RNA viral load. Initiation of ART reduced the levels of the majority of these markers. The positive effect of ART initiation was dependent on the duration of HIV infection prior to treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200170     DOI: 10.1111/j.1468-1293.2008.00661.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  20 in total

Review 1.  Biomarkers and HIV-associated cardiovascular disease.

Authors:  Jason V Baker; Daniel Duprez
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

Review 2.  Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

Authors:  Roger Bedimo; Oladapo Abodunde
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

Review 3.  Cardiovascular Disease, Statins, and HIV.

Authors:  Allison Ross Eckard; Eric G Meissner; Inderjit Singh; Grace A McComsey
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

4.  Regional gene expression of LOX-1, VCAM-1, and ICAM-1 in aorta of HIV-1 transgenic rats.

Authors:  Anne Mette Fisker Hag; Ulrik Sloth Kristoffersen; Sune Folke Pedersen; Henrik Gutte; Anne-Mette Lebech; Andreas Kjaer
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

5.  Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy.

Authors:  Katherine Krauskopf; Mark L Van Natta; Ronald P Danis; Sapna Gangaputra; Lori Ackatz; Adrienne Addessi; Alex D Federman; Andrea D Branch; Curtis L Meinert; Douglas A Jabs
Journal:  J Int Assoc Provid AIDS Care       Date:  2013 Sep-Oct

Review 6.  HIV-1, reactive oxygen species, and vascular complications.

Authors:  Kristi M Porter; Roy L Sutliff
Journal:  Free Radic Biol Med       Date:  2012-04-21       Impact factor: 7.376

7.  Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.

Authors:  Princy Kumar; Edwin DeJesus; Gregory Huhn; Louis Sloan; Catherine Butkus Small; Howard Edelstein; Franco Felizarta; Ritche Hao; Lisa Ross; Britt Stancil; Keith Pappa; Belinda Ha
Journal:  BMC Infect Dis       Date:  2013-06-07       Impact factor: 3.090

8.  Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study.

Authors:  Samir K Gupta; Changyu Shen; Sharon M Moe; Lisa M Kamendulis; Mitchell Goldman; Michael P Dubé
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

9.  Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study.

Authors:  Andreas Knudsen; Holger Jon Møller; Terese L Katzenstein; Jan Gerstoft; Niels Obel; Gitte Kronborg; Thomas Benfield; Andreas Kjaer; Anne-Mette Lebech
Journal:  BMC Infect Dis       Date:  2013-05-21       Impact factor: 3.090

10.  The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment.

Authors:  Benjamin B Gelman; Tiansheng Chen; Joshua G Lisinicchia; Vicki M Soukup; J Russ Carmical; Jonathan M Starkey; Eliezer Masliah; Deborah L Commins; Dianne Brandt; Igor Grant; Elyse J Singer; Andrew J Levine; Jeremy Miller; Jessica M Winkler; Howard S Fox; Bruce A Luxon; Susan Morgello
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.